NCT03799263

Brief Summary

The six minute walking test (6MWT) is a recognized clinical test to evaluate exercise capacity in different diseases and different conditions. The modalities of performance are described in International Guidelines. The usually reported measure is the distance in meters walked in 6 minutes. Despite the report of a single variable during the test is considered as a limit, changes in monitored variables are seldom analyzed together with the distance walked. In the past there have been some attempts of multifactorial evaluation of 6MWT, however up to date, there is no system considering together the changes of different variables. The investigators wonder whether a multidimensional index based on variables monitored during the 6MWT would better predict 24 month exacerbations and mortality in COPD patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 2, 2019

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 10, 2019

Completed
22 days until next milestone

Study Start

First participant enrolled

February 1, 2019

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2021

Completed
2.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

March 3, 2023

Status Verified

March 1, 2023

Enrollment Period

2 years

First QC Date

January 2, 2019

Last Update Submit

March 2, 2023

Conditions

Outcome Measures

Primary Outcomes (2)

  • COPD Exacerbation

    number of patients with acute exacerbations (treated with antibiotics or steroids)

    24 month

  • Mortality

    number of patients died

    24 month

Secondary Outcomes (2)

  • hospitalizations

    24 month

  • symptoms and anthropometrics characteristics correlation

    24 month

Interventions

Recordings Pneumologic assessment Severity grades (I-IV: old GOLD and A-D: new GOLD) Smoke History Drug therapy Comorbidities 6MWT performed within previous 10-14 months, if available. Measurements Standard exams usually performed at Rehab Center Lung Function tests and diffusing capacity of the lung for carbon monoxide Arterial Blood Gases Dyspnoea Health Status and Health Related Quality of Life Daily activity Lower limb muscle strength Exercise capacity

Eligibility Criteria

Age45 Years - 85 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Stable COPD patients assessed for Pulmonary Rehabilitation

You may qualify if:

  • COPD diagnosis and grades of severity as assessed by the "old" (I to IV) and "new" (A to D) GOLD guidelines (23)
  • Under inhaler therapy for ≥30 days according to guidelines (23)
  • Smokers or o ex-smokers, smoke history ≥10 pack/years (p/y)
  • Informed Consent Signature.

You may not qualify if:

  • Associated Comorbidities with short term severe prognosis
  • Actual Cardiac Arrythmias
  • Pace-maker
  • Other associated respiratory diseases
  • Chronic Heart Failure New York Heart Association classes III, IV.
  • Use of drugs influencing the heart rate
  • Changes in drug therapy in the previous 30 days
  • Use of systemic steroids or antibiotics in the previous 30 days
  • Unscheduled visits or admission to the Emergency Room for symptoms worsening in the previous 30 days
  • Pneumonia during the previous 60 days
  • Myocardial Infarction in the previous 4 months
  • Subjective and objective inability to perform the 6MWT
  • Inability to carry the oxygen cylinder.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maugeri Foundation

Tradate, VA, 21049, Italy

Location

Related Publications (6)

  • Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed). 1982 May 29;284(6329):1607-8. doi: 10.1136/bmj.284.6329.1607. No abstract available.

  • Spruit MA, Watkins ML, Edwards LD, Vestbo J, Calverley PM, Pinto-Plata V, Celli BR, Tal-Singer R, Wouters EF; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med. 2010 Jun;104(6):849-57. doi: 10.1016/j.rmed.2009.12.007. Epub 2010 May 14.

  • ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. doi: 10.1164/ajrccm.166.1.at1102. No abstract available.

  • Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, Murray S, Kazerooni EA, Gross BH, Lynch JP 3rd, Martinez FJ. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003 Nov 1;168(9):1084-90. doi: 10.1164/rccm.200302-219OC. Epub 2003 Aug 13.

  • Rodriguez DA, Kortianou EA, Alison JA, Casas A, Giavedoni S, Barberan-Garcia A, Arbillaga A, Vilaro J, Gimeno-Santos E, Vogiatzis I, Rabinovich R, Roca J. Heart Rate Recovery After 6-min Walking Test Predicts Acute Exacerbation in COPD. Lung. 2017 Aug;195(4):463-467. doi: 10.1007/s00408-017-0027-0. Epub 2017 Jun 17.

  • Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, Schunemann HJ. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J. 2008 Sep;32(3):637-43. doi: 10.1183/09031936.00140507. Epub 2008 Jun 11.

MeSH Terms

Conditions

Pulmonary Disease, Chronic ObstructiveDisease Progression

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Antonio Spanevello, Prof

    Maugeri Foundation

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

January 2, 2019

First Posted

January 10, 2019

Study Start

February 1, 2019

Primary Completion

January 31, 2021

Study Completion

December 1, 2023

Last Updated

March 3, 2023

Record last verified: 2023-03

Locations